Nucleic Acid Pathogen Testing - Cigna

← Back to document page

Medical Coverage Policy Effective Date ........................................ ..... 9/15/2021. Next Review 1/15/2022. Coverage Policy Number .................................. 0530. Nucleic acid Pathogen Testing Table of Contents Related Coverage Resources Overview ........................................ ...................... 1 Preventive Care Services Coverage General Background ........................................ ....3. Medicare Coverage Determinations ....................8. Coding/Billing Information ....................................9. References ........................................ ................36. INSTRUCTIONS FOR USE. The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients.

o human papillomavirus (HPV) cervical cancer screening • Symptomatic individuals when the associated signs and symptoms or diagnoses, are listed in the ... Chlamydial infection is the most frequently reported infectious disease in the United States (IDSA, 2018; CDC,

  Pathogens, Testing, Human, Acid, Infections, Cervical, Nucleic, Papillomavirus, Human papillomavirus, Nucleic acid pathogen testing